Literature DB >> 2775620

Stereoselectivity in the urinary excretion of the mercapturates of (R-) and (S-) alpha-bromoisovalerylurea in man.

J M te Koppele1, C Schipper, D D Breimer, G J Mulder.   

Abstract

1. alpha-Bromoisovalerylurea (BIU) is a racemic drug that is metabolized by glutathione conjugation. The urinary excretion of the separate diastereomeric mercapturates formed from (S)- and (R)-BIU in healthy young human volunteers was investigated. 2. A pronounced stereoselectivity was observed: the mercapturate formed from R-BIU was excreted with a t1/2 of 1.5 +/- 0.4 h, while that from S-BIU showed a t1/2 of 3.1 +/- 1.3 h. Moreover, 22.5 +/- 4.3 and 5.7 +/- 1.6% of the dose, respectively, was excreted as each mercapturate diastereomer in 24 h. 3. This is the first example of stereoselectivity in the elimination of a substrate for glutathione conjugation in man.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2775620      PMCID: PMC1379896          DOI: 10.1111/j.1365-2125.1989.tb05407.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Determination of monoureides in biological fluids by high-pressure-liquid-chromatography.

Authors:  M Eichelbaum; B Sonntag; G von Unruh
Journal:  Arch Toxicol       Date:  1978-12-28       Impact factor: 5.153

2.  Metabolism and biliary excretion of ethacrynic acid.

Authors:  C D Klaassen; T J Fitzgerald
Journal:  J Pharmacol Exp Ther       Date:  1974-12       Impact factor: 4.030

3.  The effect of phenobarbital, probenecid and diethyl maleate on the pharmaco-kinetics and biliary excretion of ethacrynic acid in the rat.

Authors:  J D Wallin; G Clifton; N Kaplowitz
Journal:  J Pharmacol Exp Ther       Date:  1978-05       Impact factor: 4.030

4.  alpha-Bromoisovalerylurea as model substrate for studies on pharmacokinetics of glutathione conjugation in the rat. II. Pharmacokinetics and stereoselectivity of metabolism and excretion in vivo and in the perfused liver.

Authors:  J M te Koppele; P Dogterom; N P Vermeulen; D K Meijer; A van der Gen; G J Mulder
Journal:  J Pharmacol Exp Ther       Date:  1986-12       Impact factor: 4.030

5.  alpha-Bromoisovalerylurea as model substrate for studies on pharmacokinetics of glutathione conjugation in the rat. I. (Bio-) synthesis, analysis and identification of diastereomeric glutathione conjugates and mercapturates.

Authors:  J M te Koppele; E J van der Mark; J C Olde Boerrigter; J Brussee; A van der Gen; J van der Greef; G J Mulder
Journal:  J Pharmacol Exp Ther       Date:  1986-12       Impact factor: 4.030

6.  New bromisoval (bromural) metabolites in human urine: alpha-(cystein-S-yl)isovalerylurea, alpha-(N-acetylcystein-S-yl)isovalerylurea and alpha-(cysteamin-S-yl)isovaleric acid.

Authors:  A Niederwieser; B Steinmann; A Matasovic
Journal:  J Chromatogr       Date:  1978-01-11

7.  Role of ligandin as a binding protein and as an enzyme in the biliary excretion of sulfobromophthalein.

Authors:  Z Gregus; C D Klaassen
Journal:  J Pharmacol Exp Ther       Date:  1982-04       Impact factor: 4.030

8.  Stereoselective glutathione conjugation and amidase-catalyzed hydrolysis of alpha-bromoisovalerylurea enantiomers in isolated rat hepatocytes.

Authors:  J M te Koppele; I A de Lannoy; K S Pang; G J Mulder
Journal:  J Pharmacol Exp Ther       Date:  1987-10       Impact factor: 4.030

9.  Stereoselectivity of rat liver glutathione transferase isoenzymes for alpha-bromoisovaleric acid and alpha-bromoisovalerylurea enantiomers.

Authors:  J M Te Koppele; B Coles; B Ketterer; G J Mulder
Journal:  Biochem J       Date:  1988-05-15       Impact factor: 3.857

10.  Allyl isothiocyanate: comparative disposition in rats and mice.

Authors:  Y M Ioannou; L T Burka; H B Matthews
Journal:  Toxicol Appl Pharmacol       Date:  1984-09-15       Impact factor: 4.219

View more
  1 in total

1.  Abnormal glutathione conjugation in patients with tyrosinaemia type I.

Authors:  T M Mulders; D J Bergman; B T Poll-The; G P Smit; D D Breimer; G J Mulder; M Duran; J A Smeitink
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.